Sustained Viral Response (SVR) was achieved by 44.2% of all patients receiving PEGINTRON®/REBETOL® Capsules combination therapy. Of these patients, end-of treatment response was 59.2%, with a 15.3% relapse rate.1 See below for Important Safety Information and Prescribing Information.
Maybe you've been Recently Diagnosed with hepatitis C. Or maybe you're already being treated by Taking PEGINTRON®. In either case, living with hepatitis C isn't easy and you don't have to go it alone. You've come to the right source to get the knowledge and support that you need.
Get started by browsing Treatment & Me. Read Why PEGINTRON® offers a low relapse rate. Most importantly, stay committed to your treatment. There's plenty of caring Support & Assistance to help you along the way.
The information provided on this site is not intended to be a substitute for professional medical advice. Please consult your health care provider directly with any question you may have regarding your health, condition, or treatment. Your health care provider should be your primary source of information regarding your medical condition and treatment.
Patients who are having difficulty affording Schering-Plough medications can call the Commitment to Care Patient Assistance Program at 1-800-521-7157 or visit www.pparx.org or click here for additional information.
1 Ira M. Jacobson IM, Brown Jr. RS, Freilich B. et al. Peginterferon alfa-2b and Weight-Based or Flat-Dose Ribavirin in Chronic Hepatitis C Patients: A Randomized Trial. Hepatology. October, 2007. 46(4): 971-981. Available at http://www3.interscience.wiley.com/cgi-bin/fulltext/116323744/PDFSTART. Accessed February 3, 2009
